MedElite is proud to announce a groundbreaking strategic partnership with Touro University College of Pharmacy, marking a significant milestone in the evolution of pharmaceutical care within Skilled Nursing (SNF) and Long-Term Care (LTC) facilities.
This collaboration brings together MedElite’s clinical expertise in the post-acute space and Touro University’s academic rigor to advance the study and implementation of Pharmacogenomics (PGx).
To kick off this partnership, the joint team is presenting their initial research findings at ASHP 2025 (American Society of Health-System Pharmacists) in Las Vegas—the largest and most prestigious gathering of pharmacy professionals in the nation.
Taking the Stage at ASHP 2025
Being selected to present at ASHP is a testament to the importance and quality of this research. This week, Rachel Levihaiem, PharmD, MedElite’s VP of Pharmacotherapy Services, stands alongside the faculty and researchers from Touro University to showcase how genetic insights can transform patient outcomes in nursing homes.
The research focuses on the real-world application of PGx testing in elderly populations, offering a roadmap for how facilities can move away from “trial-and-error” prescribing and toward data-driven precision medicine.
Why This Partnership Matters: The Power of PGx
Pharmacogenomics (PGx) is the study of how a patient’s unique genetic makeup affects their response to medications.
In the Long-Term Care sector, residents often manage complex chronic conditions requiring multiple medications (polypharmacy). This increases the risk of Adverse Drug Events (ADEs), which are a leading cause of preventable hospitalizations.
Through this partnership, MedElite and Touro University are exploring how PGx can be utilized to:
-
Identify ineffective medications before they are prescribed.
-
Predict adverse reactions based on genetic markers.
-
Optimize dosing for the safest, most effective therapeutic results.
A Commitment to Safer, Smarter Care
This collaboration highlights MedElite’s unwavering commitment to clinical excellence. By integrating academic research with clinical practice, we are not just following industry standards—we are helping to set them.
“Our goal has always been to ensure that every patient receives the safest, most effective care possible,” says Dr. Levihaiem. “By partnering with Touro University, we are validating that precision medicine belongs in the long-term care space. This isn’t just about science; it’s about improving the quality of life for the residents we serve every day.”
Looking Ahead
As the healthcare landscape shifts toward value-based care, the ability to prevent medication errors and reduce hospital readmissions is more critical than ever. MedElite is honored to lead this charge alongside Touro University.
We look forward to sharing more insights from our time at ASHP 2025 and continuing to drive innovation in the SNF and LTC communities.